Maria Alexandra Beatty

Ms. Maria Alexandra Beatty


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
KFKyla Frenia
Kyla Frenia
YFYunxiang Fu
Yunxiang Fu
MBMaria Alexandra Beatty
Maria Alexandra Beatty
KGKathleen Campbell Garwood
Kathleen Campbell Garwood
JKJeremy Kimmel
Jeremy Kimmel
Kevin XiaoKevin Xiao
Kevin Xiao
Background: Tear fluid, rich in proteins, is a promising source of novel biomarkers for ocular and systemic health. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the primary method for biomarker discovery. Still, factors such as limited sample volume, extracellular protein contamination, and reflex tearing can significantly impact results. Glass microcapillary tubes minimize these issues. Schirmer strips remain the most common collection method due to existing LC-MS/MS protocol optimization. Methods: In this study, we evaluated multiple digestion protocols for the shotgun quantitative LC-MS/MS analysis of small-volume tear fluid samples collected using glass capillary tubes. Protocol optimization was performed using pooled samples and then compared with the analysis of individual samples. Results: Using the optimized protocol, one μL samples were processed using a timsTOF Pro 2 mass spectrometer (Bruker) coupled online with an Evosep One liquid chromatography system (Evosep), leading to the identification of an average of 361 ± 63 proteins in pooled samples and 525 ± 123 proteins in individual small-volume tear fluid samples. Conclusions: This protocol highlights the practicality of using glass capillary tubes for comprehensive LC-MS/MS-based tear proteomics analysis, paving the way for detailed proteomics characterization of individual tear fluid samples rather than pooled samples. By shifting from pooled to individual samples, this approach greatly accelerates tear biomarker discovery, advancing precision and personalized medicine.

Verified
Journal Article
Open access
PDF file
JJJeremy Jones
Jeremy Jones
KFKyla Frenia
Kyla Frenia
JGJulia Michelle Gelman
Julia Michelle Gelman
MBMaria Alexandra Beatty
Maria Alexandra Beatty
MZMelody Zhou
Melody Zhou
KXKunhong Xiao
Kunhong Xiao
Dry Eye Disease (DED) is a complex, multifaceted ocular disease characterized by tear film instability and inflammation. It can sometimes be elusive to identify the type of DED in patients, given the overlapping symptoms with other conditions like allergies and the multitude of stimuli that might trigger DED onset. There is also difficulty due to limitations on the diagnostic testing available to clinicians, as poor reliability and a lack of standardization plague accurate diagnoses. Identified biomarkers can help identify DED pathophysiology and category, and these include molecular biomarkers like matrix metalloproteinase-9 (MMP-9), cytokines, lactotransferrin, and lacritin, as well as functional biomarkers such as tear osmolarity. Diagnostic tools, such as the InflammaDry and I-Pen Tear Osmolarity System, also now allow for point-of-care measurement of select biomarkers, including MMP-9 and osmolarity. Nonetheless, there remains a critical need for additional, reliable, and accurate diagnostic devices to better aid in the diagnosis and management of DED. This review uniquely combines a review on the current understanding of various biomarkers with an overview of the emerging technologies available to healthcare providers, aiding in better-informed diagnosis and treatment of DED.

26 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KFKyla Frenia
Kyla Frenia
YFYunxiang Fu
Yunxiang Fu
MBMaria Alexandra Beatty
Maria Alexandra Beatty
KGKathleen Campbell Garwood
Kathleen Campbell Garwood
JKJeremy Kimmel
Jeremy Kimmel
Kevin XiaoKevin Xiao
Kevin Xiao
Background/Objectives: Tear fluid, a complex biofluid that contains thousands of proteins and can be collected non-invasively, has emerged as a promising source of biomarkers for ocular and systemic health. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is currently the primary method for discovering novel biomarkers in tear fluid. However, the method of tear collection can significantly impact LC-MS/MS analysis outcomes. Tear fluid is commonly collected using either Schirmer strips or capillary tubes. While capillary tubes offer distinct advantages, such as reduced extracellular contamination and reflex tearing, most LC-MS/MS protocol development has focused on optimizing protocols for Schirmer strips. This study addresses this gap by evaluating digestion protocols for tear fluid collected with capillary tubes, focusing on biomarker discovery using small-volume samples. In this study, we evaluated multiple digestion protocols for the shotgun quantitative LC-MS/MS analysis of small-volume tear fluid samples collected using glass capillary tubes. Protocol optimization was performed using pooled samples and then compared with the analysis of individual samples. With the optimized protocol, we identified an average of 368 ± 87 proteins in pooled samples and 502 ± 127 proteins in individual small-volume tear fluid samples, using less than 1µL of total fluid volume. This protocol highlights the practicality of using glass capillary tubes for comprehensive LC-MS/MS-based tear proteomics analysis, paving the way for detailed proteomics characterization of individual tear fluid samples rather than pooled samples. By shifting from pooled to individual samples, this approach greatly accelerates tear biomarker discovery, advancing precision and personalized medicine.